meine Mail an sie, siehe unten, oben ihre Antwort:
Thank you for your email. We have not yet provided guidance on the planned product launch date. Regarding distribution, based on our business model and current plan, we do not plan to build out an internal direct sales force to support Excellagen but rather we are continuing to work with potential new collaborative commercialization partners in regards to the monetization of Excellagen. In addition, we are working with potential collaborative and strategic partners for additional product opportunities for our Excellagen formulation. To advance this process, we plan to unilaterally establish a basic distribution platform to introduce Excellagen to the market, promote and support physician adoption, and educate patients about Excellagen.
Attached please find the Excellagen Investor presentation (also on the Investors section of our website) for additional information.
Thank for your continued support and investment in Cardium. Please do not hesitate to contact me if you have any additional questions in the future.
Bonnie Ortega Director of Investor Relations Cardium Therapeutics Tel: 858-436-1018
-----Original Message----- Sent: Thursday, November 03, 2011 6:32 AM To: Bonnie Ortega Subject: Information
Dear Bonnie,
congrats to you and cardiumthx. Great that after the long waiting you received the clearance for Excellagen. It would be great to give me some answers regarding my following questions: Do you already have feedback, and overview of the interest for Ex.? Are there many people, physicians interested in Ex. and download the info you offer at your website? When are you going to start selling the product? Are you planning with a partner to commerce it?
I am looking forward for your reply. Best regards from Germany |